Cargando…

Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study

AIMS: To compare the once‐weekly glucagon‐like peptide‐1 (GLP‐1) receptor dulaglutide with the dipeptidyl peptidase‐4 (DPP‐4) inhibitor sitagliptin after 104 weeks of treatment. METHODS: This AWARD‐5 study was a multicentre, double‐blind trial that randomized participants to dulaglutide (1.5 or 0.75...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinstock, R. S., Guerci, B., Umpierrez, G., Nauck, M. A., Skrivanek, Z., Milicevic, Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008205/
https://www.ncbi.nlm.nih.gov/pubmed/25912221
http://dx.doi.org/10.1111/dom.12479
_version_ 1782451329415774208
author Weinstock, R. S.
Guerci, B.
Umpierrez, G.
Nauck, M. A.
Skrivanek, Z.
Milicevic, Z.
author_facet Weinstock, R. S.
Guerci, B.
Umpierrez, G.
Nauck, M. A.
Skrivanek, Z.
Milicevic, Z.
author_sort Weinstock, R. S.
collection PubMed
description AIMS: To compare the once‐weekly glucagon‐like peptide‐1 (GLP‐1) receptor dulaglutide with the dipeptidyl peptidase‐4 (DPP‐4) inhibitor sitagliptin after 104 weeks of treatment. METHODS: This AWARD‐5 study was a multicentre, double‐blind trial that randomized participants to dulaglutide (1.5 or 0.75 mg) or sitagliptin 100 mg for 104 weeks or placebo (reported separately) for 26 weeks. Change in glycated haemoglobin (HbA1c) concentration from baseline was the primary efficacy measure. A total of 1098 participants with HbA1c concentrations ≥7.0% (≥53.0 mmol/mol) and ≤9.5% (≤80.3 mmol/mol) were randomized, and 657 (59.8%) completed the study. We report results for dulaglutide and sitagliptin at the final endpoint. RESULTS: Changes in HbA1c at 104 weeks were (least squares mean ± standard error) −0.99 ± 0.06% (−10.82 ± 0.66 mmol/mol), −0.71 ± 0.07% (−7.76 ± 0.77 mmol/mol) and −0.32 ± 0.06% (−3.50 ± 0.66 mmol/mol) for dulaglutide 1.5 mg, dulaglutide 0.75 mg and sitagliptin, respectively (p < 0.001, both dulaglutide doses vs sitagliptin). Weight loss was greater with dulaglutide 1.5 mg (p < 0.001) and similar with 0.75 mg versus sitagliptin (2.88 ± 0.25, 2.39 ± 0.26 and 1.75 ± 0.25 kg, respectively). Gastrointestinal adverse events were more common with dulaglutide 1.5 and 0.75 mg versus sitagliptin (nausea 17 and 15% vs 7%, diarrhoea 16 and 12% vs 6%, vomiting 14 and 8% vs 4% respectively). Pancreatic, thyroid, cardiovascular and hypersensitivity safety were similar across groups. CONCLUSIONS: Dulaglutide doses provided superior glycaemic control and dulaglutide 1.5 mg resulted in greater weight reduction versus sitagliptin at 104 weeks, with acceptable safety.
format Online
Article
Text
id pubmed-5008205
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-50082052016-09-16 Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study Weinstock, R. S. Guerci, B. Umpierrez, G. Nauck, M. A. Skrivanek, Z. Milicevic, Z. Diabetes Obes Metab Original Articles AIMS: To compare the once‐weekly glucagon‐like peptide‐1 (GLP‐1) receptor dulaglutide with the dipeptidyl peptidase‐4 (DPP‐4) inhibitor sitagliptin after 104 weeks of treatment. METHODS: This AWARD‐5 study was a multicentre, double‐blind trial that randomized participants to dulaglutide (1.5 or 0.75 mg) or sitagliptin 100 mg for 104 weeks or placebo (reported separately) for 26 weeks. Change in glycated haemoglobin (HbA1c) concentration from baseline was the primary efficacy measure. A total of 1098 participants with HbA1c concentrations ≥7.0% (≥53.0 mmol/mol) and ≤9.5% (≤80.3 mmol/mol) were randomized, and 657 (59.8%) completed the study. We report results for dulaglutide and sitagliptin at the final endpoint. RESULTS: Changes in HbA1c at 104 weeks were (least squares mean ± standard error) −0.99 ± 0.06% (−10.82 ± 0.66 mmol/mol), −0.71 ± 0.07% (−7.76 ± 0.77 mmol/mol) and −0.32 ± 0.06% (−3.50 ± 0.66 mmol/mol) for dulaglutide 1.5 mg, dulaglutide 0.75 mg and sitagliptin, respectively (p < 0.001, both dulaglutide doses vs sitagliptin). Weight loss was greater with dulaglutide 1.5 mg (p < 0.001) and similar with 0.75 mg versus sitagliptin (2.88 ± 0.25, 2.39 ± 0.26 and 1.75 ± 0.25 kg, respectively). Gastrointestinal adverse events were more common with dulaglutide 1.5 and 0.75 mg versus sitagliptin (nausea 17 and 15% vs 7%, diarrhoea 16 and 12% vs 6%, vomiting 14 and 8% vs 4% respectively). Pancreatic, thyroid, cardiovascular and hypersensitivity safety were similar across groups. CONCLUSIONS: Dulaglutide doses provided superior glycaemic control and dulaglutide 1.5 mg resulted in greater weight reduction versus sitagliptin at 104 weeks, with acceptable safety. Blackwell Publishing Ltd 2015-05-20 2015-09 /pmc/articles/PMC5008205/ /pubmed/25912221 http://dx.doi.org/10.1111/dom.12479 Text en © 2015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Weinstock, R. S.
Guerci, B.
Umpierrez, G.
Nauck, M. A.
Skrivanek, Z.
Milicevic, Z.
Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study
title Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study
title_full Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study
title_fullStr Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study
title_full_unstemmed Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study
title_short Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study
title_sort safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (award‐5): a randomized, phase iii study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008205/
https://www.ncbi.nlm.nih.gov/pubmed/25912221
http://dx.doi.org/10.1111/dom.12479
work_keys_str_mv AT weinstockrs safetyandefficacyofonceweeklydulaglutideversussitagliptinafter2yearsinmetformintreatedpatientswithtype2diabetesaward5arandomizedphaseiiistudy
AT guercib safetyandefficacyofonceweeklydulaglutideversussitagliptinafter2yearsinmetformintreatedpatientswithtype2diabetesaward5arandomizedphaseiiistudy
AT umpierrezg safetyandefficacyofonceweeklydulaglutideversussitagliptinafter2yearsinmetformintreatedpatientswithtype2diabetesaward5arandomizedphaseiiistudy
AT nauckma safetyandefficacyofonceweeklydulaglutideversussitagliptinafter2yearsinmetformintreatedpatientswithtype2diabetesaward5arandomizedphaseiiistudy
AT skrivanekz safetyandefficacyofonceweeklydulaglutideversussitagliptinafter2yearsinmetformintreatedpatientswithtype2diabetesaward5arandomizedphaseiiistudy
AT milicevicz safetyandefficacyofonceweeklydulaglutideversussitagliptinafter2yearsinmetformintreatedpatientswithtype2diabetesaward5arandomizedphaseiiistudy